These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 16816797)

  • 21. Tardive dyskinesia and atypical antipsychotic drugs.
    Casey DE
    Schizophr Res; 1999 Mar; 35 Suppl():S61-6. PubMed ID: 10190226
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs.
    Peluso MJ; Lewis SW; Barnes TR; Jones PB
    Br J Psychiatry; 2012 May; 200(5):387-92. PubMed ID: 22442101
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review.
    Gao K; Kemp DE; Ganocy SJ; Gajwani P; Xia G; Calabrese JR
    J Clin Psychopharmacol; 2008 Apr; 28(2):203-9. PubMed ID: 18344731
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The stable patient with schizophrenia--from antipsychotic effectiveness to adherence.
    Thomas P
    Eur Neuropsychopharmacol; 2007 Mar; 17 Suppl 2():S115-22. PubMed ID: 17336766
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia.
    Addington DE; Mohamed S; Rosenheck RA; Davis SM; Stroup TS; McEvoy JP; Swartz MS; Lieberman JA
    J Clin Psychiatry; 2011 Jan; 72(1):75-80. PubMed ID: 20868641
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine.
    Tada M; Shirakawa K; Matsuoka N; Mutoh S
    Psychopharmacology (Berl); 2004 Oct; 176(1):94-100. PubMed ID: 15083255
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M; Krupka-Matuszczyk I
    Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improving outcome in schizophrenia: the potential importance of EPS and neuroleptic dysphoria.
    Gerlach J
    Ann Clin Psychiatry; 2002 Mar; 14(1):47-57. PubMed ID: 12046640
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Extrapyramidal side effects are unacceptable.
    Kane JM
    Eur Neuropsychopharmacol; 2001 Oct; 11 Suppl 4():S397-403. PubMed ID: 11587887
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The roles of efficacy, safety, and tolerability in antipsychotic effectiveness: practical implications of the CATIE schizophrenia trial.
    Nasrallah HA
    J Clin Psychiatry; 2007; 68 Suppl 1():5-11. PubMed ID: 17286522
    [TBL] [Abstract][Full Text] [Related]  

  • 31. EPS profiles: the atypical antipsychotics are not all the same.
    Weiden PJ
    J Psychiatr Pract; 2007 Jan; 13(1):13-24. PubMed ID: 17242588
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: Incidence and management strategies in patients with schizophrenia.
    Margolese HC; Chouinard G; Kolivakis TT; Beauclair L; Miller R; Annable L
    Can J Psychiatry; 2005 Oct; 50(11):703-14. PubMed ID: 16363464
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adverse effects of the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations.
    J Clin Psychiatry; 1998; 59 Suppl 12():17-22. PubMed ID: 9766615
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia.
    Casey DE
    Schizophr Res; 1991; 4(2):109-20. PubMed ID: 1674881
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of treatment-emergent extrapyramidal symptoms in patients with bipolar mania or schizophrenia during olanzapine clinical trials.
    Cavazzoni PA; Berg PH; Kryzhanovskaya LA; Briggs SD; Roddy TE; Tohen M; Kane JM
    J Clin Psychiatry; 2006 Jan; 67(1):107-13. PubMed ID: 16426096
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Second-generation antipsychotics for schizophrenia: can we resolve the conflict?
    Leucht S; Kissling W; Davis JM
    Psychol Med; 2009 Oct; 39(10):1591-602. PubMed ID: 19335931
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia.
    Tran PV; Dellva MA; Tollefson GD; Beasley CM; Potvin JH; Kiesler GM
    J Clin Psychiatry; 1997 May; 58(5):205-11. PubMed ID: 9184614
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study.
    Gharabawi GM; Bossie CA; Zhu Y; Mao L; Lasser RA
    Schizophr Res; 2005 Sep; 77(2-3):129-39. PubMed ID: 15913962
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Extrapyramidal side effects of antipsychotic treatment: scope of problem and impact on outcome.
    Tandon R; Jibson MD
    Ann Clin Psychiatry; 2002 Jun; 14(2):123-9. PubMed ID: 12238737
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mid-term and long-term efficacy and effectiveness of antipsychotic medications for schizophrenia: a data-driven, personalized clinical approach.
    Glick ID; Correll CU; Altamura AC; Marder SR; Csernansky JG; Weiden PJ; Leucht S; Davis JM
    J Clin Psychiatry; 2011 Dec; 72(12):1616-27. PubMed ID: 22244023
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.